Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer

PURPOSE: KRAS is mutated in the majority of pancreatic ductal adenocarcinoma. MAPK and PI3K-AKT are primary KRAS effector pathways, but combined MAPK and PI3K inhibition has not been demonstrated to be clinically effective to date. We explore the resistance mechanisms uniquely employed by malignant...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cancer Res
Auteurs principaux: Ponz-Sarvise, Mariano, Corbo, Vincenzo, Tiriac, Hervé, Engle, Dannielle D., Frese, Kristopher K., Oni, Tobiloba E., Hwang, Chang-Il, Öhlund, Daniel, Chio, Iok In Christine, Baker, Lindsey A., Filippini, Dea, Wright, Kevin, Bapiro, Tashinga E., Huang, Pearl, Smith, Paul, Yu, Kenneth H., Jodrell, Duncan I, Park, Youngkyu, Tuveson, David A.
Format: Artigo
Langue:Inglês
Publié: 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6858952/
https://ncbi.nlm.nih.gov/pubmed/31492749
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1398
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires